在伊朗伊斯法罕的患者中,药物坚持及其与自尊的关系
Moien Motioleslam1, Malek Fereidooni-Moghadam2, Masood Etemadifar3
1Nursing and Midwifery Care Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Epilepsy & behavior : E&B
|April 18, 2024
概括
在中服药的坚持与自尊有关. 提高自尊可以提高患者抗发作药物的服药性.
科学领域:
- 神经学 神经学
- 心理学 心理学 心理学
背景情况:
- 药物坚持对于治疗和实现治疗结果至关重要.
- 自尊是一个心理因素,可能会影响患者服用抗发作药物 (ASM).
研究的目的:
- 为了研究患者的药物坚持.
- 在PWE中探索自尊和药物坚持之间的关系.
主要方法:
- 一项描述性分析研究于2021年在伊朗伊斯法罕进行.
- 250名患者 (PWE) 使用连续采样进行了招募.
- 数据采集使用人口信息,罗森伯格自尊度量表和莫里斯基药物坚持调查问卷.
主要成果:
- 平均坚持得分为6.9±2.02,其中46.4%的参与者表现出较低的坚持.
- 平均自尊评分为5.11 ± 2.11.11 分.
- 在药物坚持和自尊之间发现了显著的正相关性 (rs = 0.464,p = 0.00).
结论:
- 在患者中,自尊和药物坚持之间存在统计学上显著的正相关性.
- 旨在提高自尊心的干预措施可以改善PWE患者的药物坚持.
更多相关视频
08:23A Multimodal Imaging- and Stimulation-based Method of Evaluating Connectivity-related Brain Excitability in Patients with Epilepsy
Published on: November 13, 2016
11.2K
04:51Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
Published on: April 11, 2019
9.4K
相关概念视频
Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
Antiepileptic Drugs: Potassium Channel Activators
176
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
176
Arteries of the Lower Limbs
188
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
188
Psychosis: Goals of Pharmacotherapy
124
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
124
The Placebo Effect
6.2K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
288
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
288
